Biotest AG — M&A Activity 2006

May 3, 2006

News Details

Ad-hoc | 3 May 2006 19:46

Biotest AG:Biotest and Sanquin plan a strategic alliance in plasma products

Ad hoc announcement transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— Biotest and Sanquin plan a strategic alliance in plasma products Amsterdam/ Dreieich, 3 May 2006. Collaborating successfully for over 20 years already, Biotest AG, Dreieich, Germany and the Sanquin Blood Supply Foundation (“Sanquin”), Amsterdam, The Netherlands now plan to pool their activities in the area of producing and developing plasma products. Parties have agreed to enter into discussions preparing a joint-business plan for their plasma product manufacturing activities. If the outcome of the negotiations is positive, Sanquin will integrate the manufacturing activities of its Plasma Products Division into Biotest Pharma GmbH, currently a subsidiary of Biotest AG, with Sanquin receiving a share in this company in return. Following the possible transaction, the Biotest Group will own a majority shareholding in Biotest Pharma GmbH and the company will be included in the Group’s scope of consolidation. Biotest and Sanquin will continue to operate independently in the sales of pharmaceutical plasma products. The other business segments of Biotest will not be part of the deal. Likewise, the activities of Sanquin securing self-sufficiency in The Netherlands for (cellular) blood components and plasma products will not be affected. According to current plans the joint venture will be managed by a joint management team of Biotest and Sanquin. By combining their activities in plasma protein manufacturing, Biotest and Sanquin anticipate substantial synergy effects through streamlining the entire product range, accelerating research and development projects, optimising production and procurement procedures and reducing the volume of investment. The joint-venture can expect to process more than one million litres of plasma, and will be at level with the other major global manufacturers of plasma products. Biotest AG: Dr. Michael Ramroth, Tel. +49 6103 801-338 Fax: +49 6103 801-347, e-mail: michael.ramroth @biotest.de Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de (c)DGAP 03.05.2006 ————————————————————————— language: English emitter: Biotest AG Landsteinerstr. 5 63303 Dreieich Deutschland phone: +49 – 6103 / 801 – 0 fax: +49 – 6103 / 801 – 150 email: mail@biotest.de WWW: www.biotest.de ISIN: DE0005227201, DE0005227235 WKN: 522720, 522723 indexes: stockmarkets: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin-Bremen, Düsseldorf, Hamburg, Stuttgart End of News DGAP News-Service —————————————————————————